1 week ago
2
Sviatlana Barchan/iStock via Getty Images
Novo Nordisk (NVO) and Eli Lilly & Co. (NYSE:LLY), the global leaders in obesity medications, are now facing their first major competitor in China.
Suzhou-based Innovent Biologics (OTCPK:IVBIY) (OTCPK:IVBXF) gained regulatory approval last week for its
English (US) ·